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ABSTRACT 80 
Context: in 2007, a large retrospective case-control study provided evidence that adjuvant mitotane prolongs 81 
recurrence-free survival (RFS) in patients with radically resected adrenocortical carcinoma (ACC).  82 
Objective and design: We aimed to confirm the prognostic role of adjuvant mitotane in the same series after 9 83 
additional years of follow-up. 84 
Setting, Patients and Interventions: 162 ACC patients included in the previous study, who did not recur or die after a 85 
landmark period of 3 months, were considered. 47 patients were enrolled in 4 Italian centers where adjuvant mitotane 86 
was routinely recommended (mitotane group), 45 patients in 4 Italian centers where no adjuvant strategy was 87 
undertaken (control group 1), and 70 German patients left untreated after surgery (control group 2).  88 
Main Outcome Measures: The primary aim was RFS, the secondary was overall survival (OS). 89 
Results: at multivariate analysis, an increased risk of recurrence was found in both control cohorts (group 1: Hazard 90 
Ratio [HR] 2.98, 95% CI: 1.75-5.09, p <0.0001; group 2: HR 2.61, 95% CI: 1.56-4.36, p <0.0001) compared to the 91 
mitotane group. The risk of death was significantly higher in control group 1 (HR 2.03 95% CI:1.17-3.51 p = 0.011) but 92 
not in control group 2 (HR 1.60, 95% CI: 0.94-2.74, p = 0.083), which had better prognostic factors and more 93 
aggressive treatment of recurrences than control group 1. The benefit of adjuvant mitotane on RFS was observed 94 
regardless of the hormone secretory status. 95 
Conclusions: adjuvant mitotane is associated with prolonged RFS, without any apparent influence by the tumor 96 
secretory status. The retrospective nature of the study is a major limitation. 97 
98 
  
INTRODUCTION 99 
Radical surgery can potentially cure patients with ACC, a rare and aggressive endocrine malignancy (1). However, 100 
ACC has a high propensity to recur and tumor recurrence affects significantly life expectancy of ACC patients (2-4). 101 
Although complete tumor removal is an important prognostic factor, achieving a R0 status does not prevent disease 102 
recurrence (1-4). This provides a rationale for adjuvant therapy and mitotane, an adrenolytic drug with an established 103 
role in the treatment of patients with advanced ACC, has been used in the adjuvant setting (1).  104 
In 2007, we reported the results of a multicenter, retrospective, case-control study comparing the outcome of ACC 105 
patients managed at some Italian centers, where adjuvant mitotane treatment was used following radical surgery, with 106 
that of patients managed at other Italian centers, where adjuvant strategies were not adopted. To further control for 107 
potential biases, a cohort of German patients who were treated with surgery only was added as a second control group 108 
(5). The main strength of this study was that it included patients whose treatment assignment was not related to their 109 
characteristics but to the center policy. Recurrence free survival (RFS) was significantly prolonged in the mitotane 110 
group when compared with both control groups. Therefore, the study provided evidence that adjuvant mitotane may be 111 
of benefit to patients with radically resected ACC. The retrospective nature of the study, however, does not allow to 112 
definitively support adjuvant mitotane treatment for all patients. The study renewed interest in adjuvant mitotane 113 
treatment, but attracted criticisms (1,6). A major concern was the duration of follow-up, which was considered not long 114 
enough due to a relatively low number of recurrences and deaths in patients receiving adjuvant mitotane.  115 
In the present study, we report the long-term outcomes of the original patient series with 9 additional years of follow-116 
up. The primary aim was to confirm the prognostic role of adjuvant mitotane therapy on RFS; secondary aims were to 117 
assess the effects of mitotane on overall survival (OS) and the predictive role of cortisol hypersecretion on mitotane 118 
efficacy.  119 
120 
  
PATIENTS AND METHODS 121 
The study details were reported previously (5). Briefly, we reviewed the outcome of 102 consecutive patients with ACC 122 
who had undergone radical surgery at 8 tertiary referral centers in Italy from 1985 through 2003. Inclusion criteria were 123 
age greater than 18 years, pathological diagnosis of ACC and the availability of preoperative and postoperative 124 
computed tomographic (CT) or magnetic resonance imaging (MRI) scans. Exclusion criteria were macroscopically 125 
incomplete resection, incomplete tumor staging, concomitant cancers within the previous 5 years, clinically significant 126 
concomitant diseases, and adjuvant therapies other than mitotane. Forty-seven patients were enrolled in 4 centers where 127 
adjuvant mitotane was recommended irrespective of patient and tumor characteristics (mitotane group), while 55 128 
patients were enrolled in 4 centers where no adjuvant strategy was undertaken after surgery (control group 1). The 129 
German control group comprised 75 ACC patients from the German Adrenocortical Carcinoma Registry with available 130 
information on diagnostic procedures, surgical outcomes, and follow-up similar to those used to evaluate the Italian 131 
study population (control group 2). The institutional ethics committee at each clinical center approved the study. 132 
Complete resection was defined as no evidence of macroscopic residual disease on the basis of surgical reports, 133 
histopathological analysis, and postoperative imaging. All histologic diagnoses were confirmed by experienced 134 
pathologists and reviewed centrally in more than 75% of cases (6). Staging was reported according to the McFarlane–135 
Sullivan criteria (4). Follow-up visits, including images, were performed every 6 months. Disease recurrence was 136 
defined as radiologic evidence of a new lesion during follow-up. Follow-up for this study was closed in December 137 
2013. 138 
The primary aim was to compare RFS, defined as the time elapsing from the date of surgery to the first documentation 139 
of recurrence, in patients who received adjuvant mitotane therapy with that of patients who did not. Secondary aims 140 
were OS, defined as the time elapsing from the date of surgery to the date of death. For both RFS and OS, patients who 141 
did not experience the event (recurrence or death, respectively) were censored at the time of last follow-up examination.  142 
Data analysis was done using SPSS version 17 (SPSS Inc, IBM). RFS and OS were estimated according to the Kaplan-143 
Meier method; the respective comparisons between groups were performed using the log-rank test. The Cox regression 144 
model was used to assess in univariate and multivariate analyses the predictive role of mitotane treatment, clinical and 145 
pathological variables on RFS and OS. The likelihood ratio was used to assess the significance of covariates included in 146 
each model. All p values are 2-sided and results were considered significant at p ≤ .05. The Cox analysis was also used 147 
to assess the presence of heterogeneity in the prognostic effect of the cortisol excess in patients stratified according to 148 
hormone secretion. In these subgroups, any modification of the prognostic effect was assessed by including the 149 
appropriate covariate interaction terms in the model. To reduce the inherent bias of patients with early progression and 150 
  
death, all survival analyses were performed with the landmark method, using a fixed landmark point at month 3. 151 
Patients who experienced the event (recurrence or death) before the landmark point were excluded from the analysis. 152 
153 
  
RESULTS 154 
Of the 177 patients included in the original study (5), 15 recurred or died within the first 3 months (landmark point), 10 155 
patients in the control group 1 and 5 patients in the control group 2, and were therefore excluded from the present 156 
analysis. Among the fully assessable 162 patients, 47 patients received adjuvant mitotane (mitotane group), 45 patients 157 
formed the control group 1, and 70 patients the control group 2. Patient characteristics are detailed in Table 1.  158 
The mitotane group and control group 1 were well balanced with respect to tumor stage, hormone secretory status, and 159 
Weiss score. The control group 2 had a lower proportion of patients with stage III-IV ACC than the mitotane group. In 160 
addition, patients in the control group 2 were significantly older than patients in the mitotane group. There were no 161 
major differences in the surgical approach among the various groups as most patients of all groups underwent open 162 
surgery compared to laparoscopic surgery (mitotane group, 94%, control group 1, 96%, and control group 2, 89%, 163 
respectively). 164 
The median follow-up period after surgery of surviving patients at the last follow-up examination was 141 months 165 
(range, 42 to 199) in the mitotane group, 142 months (range, 25 to 219) in the control group 1, and 128 months (range, 166 
38 to 323) in the control group 2. Recurrence was documented in 121 patients (75%), 25 in the mitotane group (53%), 167 
40 in the control group 1 (89%), and 56 in the control group 2 (80%), respectively. The pattern of recurrence between 168 
the 3 groups was comparable and is detailed in Table 2. Treatment of recurrence included more frequently surgery in 169 
both the mitotane group and control group 2 than control group 1 (64%, 66% and 35%, respectively). 170 
Death from ACC was reported in 100 patients (62%): 23 in the mitotane group (49%), 36 (90%) in the control group 1 171 
and 41 (59%) in the control group 2, respectively. 172 
Mitotane was given following a low-dose regimen (7) and median duration of adjuvant treatment was 42 months (range 173 
4-162 months). Of the mitotane-treated patients, 11 patients suspended treatment while being free of disease as a 174 
decision of the treating physicians (end of the planned course of therapy), 5 patients discontinued definitively mitotane 175 
for toxicity (1 for leucopenia, 1 for elevation in liver enzymes, 2 for general toxicity and 1 for neurological toxicity, 176 
respectively) and 2 discontinued mitotane at the time of disease recurrence. Mitotane was continued in the other patients 177 
with recurrent ACC. Adverse events of mitotane treatment are given in Table 3.  178 
Mitotane treatment was associated with longer RFS compared with both control groups (Figure 1A). The median RFS 179 
was 42 months in the mitotane group, 17 months in the control group 1 (p <0.001), and 26 months in the control group 180 
2 (p = 0.005). The median OS was 161 months in the mitotane group, compared with 65 months in the control group 1 181 
(p = 0.007) and 92 months in the control group 2 (p = 0.28), respectively (Figure 1B). 182 
Table 4 reports the results of the univariate and multivariate Cox analyses. Adjuvant mitotane treatment was an 183 
independent predictive factor for RFS in multivariate analysis after adjusting for age, sex and tumor stage. The risk of 184 
  
recurrence was significantly higher either in the control group 1 (Hazard Ratio [HR] 2.98, 95% Confidence Interval 185 
[CI]: 1.75-5.09, p <0.0001) or in the control group 2 (HR 2.61, 95% CI: 1.56-4.36, p <0.0001) when compared with the 186 
mitotane group. 187 
Adjuvant mitotane treatment was also an independent predictive factor for OS in multivariate analysis after adjusting 188 
for age, sex and tumor stage. In comparison to the mitotane group, the risk of death was significantly higher in the 189 
control group 1 (HR 2.03, 95% CI:1.17-3.51 p = 0.011) but not in the control group 2 (HR 1.60, 95% CI:  0.94-2.74, p = 190 
0.083). 191 
The efficacy of adjuvant mitotane was also explored stratifying patients according to cortisol secretion by ACC in 137 192 
evaluable patients.  Mitotane effect on RFS did not differ according to the presence of overt cortisol excess. The risk of 193 
recurrence was higher in control groups 1 and 2 than in the mitotane group, both in patients with non-secreting tumors 194 
(HR 2.16, 95% CI: 1.12-4.17, p = 0.022 and HR 2.00, 95% CI: 0.93-4.34, p = 0.077, respectively) and in patients with 195 
cortisol-secreting ACC (HR 4.51, 95% CI: 1.92-10.60, p = 0.001 and HR 1.79, 95% CI: 0.86-3.73, p = 0.12, 196 
respectively). When assessing HR values in control group 2, it has to be considered that only 45 out of 70 patients 197 
(64%) were evaluable for ACC secretion. 198 
199 
  
DISCUSSION 200 
The evidence on adjuvant mitotane therapy after radical resection of ACC is sparse and flawed by several limitations, 201 
such as limited statistical power, absence of a matched control group, RFS not uniformly defined and response duration 202 
unclearly reported. Moreover, all studies but one were retrospective and employed different formulations of mitotane at 203 
variable doses, ranging from 3 to 20 grams daily (Table 5). On this scenario, the most informative data were provided 204 
by our retrospective case-control study involving a large cohort of ACC patients who were assigned to adjuvant 205 
mitotane or no treatment independently on patient’s characteristics (5). The study included a group of mitotane-treated 206 
patients and 2 contemporary, control groups of untreated patients matched for the major prognostic factors (actually the 207 
control group 2 had better prognostic features). This is strength of the study, since in other studies the presence of 208 
unfavorable characteristics was likely a factor supporting the decision to prescribe adjuvant mitotane and this have 209 
introduced biased data (Table 3). Very recently, Postlewait et al. (23) reported a retrospective analysis of the outcomes 210 
of 207 ACC patients who underwent resection at 13 centers in the US. They found that adjuvant mitotane was 211 
associated with decreased RFS and OS. The difference with our results may be readily explained by the selection of 212 
patients at unfavorable prognosis for mitotane treatment. The patients who were treated with mitotane had a higher 213 
frequency of stage IV, metastatic tumors and indeed chemotherapy was frequently associated to mitotane therapy. Also 214 
the frequency of cortisol excess, another negative prognostic factor, was more frequent in the mitotane group. Since 215 
42% of the 88 patients treated with mitotane had stage IV ACC, this series is not comparable to our ones, with only 216 
13% stage IV ACC. 217 
Though the retrospective nature of our study is a major limitation, the rarity of ACC makes challenging the organization 218 
of a prospective randomized clinical trial. As a matter of fact, we are currently undertaking the first randomized, 219 
controlled trial in patients with ACC following radical extirpation, the ADIUVO study (www-adiuvo-trial.org), but 220 
recruitment is difficult and results are not expected before several years. Meanwhile, physicians who are treating ACC 221 
are left with the dilemma of prescribing or not post-operative mitotane treatment (6). To provide guidance in this 222 
controversial area, a panel of experts recommended adjuvant mitotane in radically resected ACC patients at high risk of 223 
recurrence (24), and this recommendation has been incorporated in currently available guidelines (1, 25). 224 
Therefore, we re-analyzed the outcome data of the original patient cohorts after a longer follow-up, more than 9 years 225 
after the end of the original study.  226 
To reduce the “immortal-time” bias, in the updated analysis we calculated RFS and OS estimates from the time point of 227 
3 months (landmark method), thus excluding from the analysis the patients with early progression and death. We set the 228 
landmark point at 3 months because at that time mitotane treatment has been started in all patients. With the 229 
introduction of the landmark analysis the median RFS of patients in the control group 1 increased consistently in this 230 
  
study as opposed to the original one (17 vs 10 months) while the difference was marginal in the control group 2 (26 vs 231 
25 months). Even with the introduction of a landmark analysis and after a median follow-up of more than 10 years, the 232 
significant advantage in terms of reduction of the risk of recurrence of patients who underwent adjuvant mitotane 233 
compared to patients of both control groups was confirmed both in univariate and multivariate analyses. Mitotane 234 
treated patients had also a significant longer survival than patients included in the control group 1, while the survival 235 
advantage over the control group 2 just failed to attain the statistical significance. However, the control group 2 had a 236 
better risk profile, with a significantly higher percentage of stage I-II tumors, portending improved outcome. Moreover, 237 
treatment of recurrences was more aggressive in the control group 2 than in control group 1. Although the pattern of 238 
recurrence between the 3 groups was comparable, with local recurrences found in about 50% of cases, surgery was most 239 
frequently used in both the mitotane group and control group 2 than in control group 1 (64%, 66% and 35%, 240 
respectively). Since surgical approaches are generally regarded as superior to treatment regimens consisting only of 241 
medical therapy to manage recurrent ACC (2, 26, 27), we may argue that this difference in the management contributed 242 
to the better overall survival observed in the control group 2 than control group 1.  243 
The recently published experience of the University of Michigan with adjuvant therapies for ACC shows that adjuvant 244 
mitotane treatment was associated with a significantly prolonged RFS in multivariate analysis (HR 0.723, 95%CI: 245 
0.533-0.981, p = 0.037) although the effect on OS did not reach levels of significance (HR 0.887, 95% CI: 0.621-1.268, 246 
p = 0.511) (22). 247 
Another point of controversy is whether mitotane could be better suited to treat secreting ACC, due to its inhibitory 248 
effects on adrenal steroidogenesis. In a French series of 166 patients, mitotane was not effective in improving RFS in 249 
the overall cohort, although in the subgroup of patients with cortisol excess a tendency towards a beneficial effect was 250 
seen (18). This finding raised the issue that the efficacy of adjuvant mitotane therapy may be limited to patients with 251 
cortisol-secreting tumors. However, cortisol was not a predictor of adjuvant mitotane efficacy in a large, multicenter, 252 
dataset recently published (28). In the present study, the efficacy of mitotane on RFS did not differ when patients were 253 
stratified by presence of cortisol excess. These data further support the antineoplastic activity of mitotane irrespective of 254 
the cortisol secretory status. 255 
In conclusion, this updated analysis with longer follow-up and landmark analysis confirms that among patients with 256 
macroscopically complete removal of ACC, the use of adjuvant mitotane compared with observation is associated with 257 
prolonged RFS independently of hormone activity. We think that the present results strengthen the recommendation of 258 
adjuvant mitotane as part of the post-operative management of ACC patients. Another important finding is that an 259 
aggressive use of surgery to treat ACC recurrences may be associated with prolonged survival. Repeat surgery 260 
for recurrent ACC may provide a benefit in overall survival independently from mitotane use. These data are of 261 
  
particular interest for surgeons operating on ACC patients, who should refer these patients to centers with specific 262 
expertise on surgical treatment of ACC and management of mitotane therapy. Interestingly, early referral of stage 263 
II ACC patients to specialized centers has been associated with an improved outcome (20). The retrospective nature of 264 
the study does not allow to establish definitively the value of adjuvant mitotane treatment. There might be subsets of 265 
patients, i.e. patients with small, low-grade tumors, who may not benefit from a strategy of adjuvant mitotane treatment. 266 
A currently ongoing randomized trial (ADIUVO study) is specifically aiming to establish mitotane efficacy in patients 267 
at low/intermediate risk of recurrence. 268 
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